PREDICT CLINICAL AND BLEEDING RISKS ON DECISION OF DURATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGONE PERCUTANEOUS CORONARY INTERVENTION

Clinical decision making surrounding the optimal duration and combination of dual antiplatelet therapy (DAPT) must be done in acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI). Currently, there is no risk prediction tools for the long-term clinical and